

myMedidata — Medidata's Patient Portal

Background

In the last 50 years, technology advancements have improved efficiencies across a variety of industries. Yet with over 330,000 clinical trials conducted annually — addressing some of the most daunting medical challenges, not much has changed in the way clinical trials are conducted. Some of the bigger challenges in running a clinical trial are recruiting enough patients (in part due to lack of awareness or understanding of clinical trials by potential subjects), retaining those patients once recruited and enrolled, and ensuring they remain compliant throughout the completion of the study. Almost 80% of sites fail to meet enrollment rates¹, prolonging new treatments for those affected by life-threatening and debilitating diseases such as cancer, heart disease, Alzheimer's Disease, and diabetes. By incorporating the use of technology, data capture will no longer be restricted to physical site visits - increasing patient participation.

Patient-related Challenges and Their Impact to Traditional Clinical Trials

One of the biggest components to clinical research is the patient's ability to participate. By making research more patient-centric and giving patients the ability to virtually access and actively engage in their trials, we lower the patient burden, which in return increases engagement and retention rates. Traditional trial processes need to be disrupted and simplified to create a more seamless patient experience. Virtual clinical trial visits allow sponsors and researchers to directly collect symptoms from research participants who may not otherwise be able to continue with traditional site visits. In addition, sponsors can screen patients and review medical records virtually, enlarging the number of potential trial subjects, which ultimately increases recruitment and enrollment rates. The following statistics demonstrate the impact of patient-related challenges on clinical studies.

23%

of patients are dissatisfied with site location²

58%

increase in number of investigative sites due to increasing trial complexity³

30%

of trials are canceled due to insufficient participation⁴

30%

patient drop out before the study ends⁵

4 of 5

sites fail to enroll to targets⁶

80%

drop in new patients entering trials at the global peak of COVID-19⁷

¹ 2012 Clinical trial delays: America's patient recruitment dilemma ² 2017 CISCPR Perceptions & Insights Study


³ 2015 Tufts: The Cost of Clinical Trial Delays ⁴ 2015 Why Clinical Trials Are Terminated

⁵ National Academy of Sciences . The Prevention and Treatment of Missing Data in Clinical Trials. Washington, D.C.: National Academies Press; 2010. Available at: www.nap.org

⁶ 2012 Clinical trial delays: America's patient recruitment dilemma ⁷ Covid-19 & Clinical Trials — The Medidata Perspective

Medidata’s Patient Portal — myMedidata

Medidata’s patient portal — myMedidata — is a single-destination platform enabling patients to enroll and participate in clinical trial activities. This platform is the industry’s most comprehensive solution for all aspects of site and remote-based clinical research. myMedidata encompasses all of the capabilities of Medidata’s patient-facing solutions for electronic patient consent and clinical outcomes assessment (eCOA), collection of critical data through wearable and other biosensors, COVID-19 symptom tracking, live video investigator/patient visits, and enablement of hybrid and virtual trials. Using myMedidata, patients can easily complete forms, participate in video visits with their study team, receive reminders and notifications for study-related tasks, and access their results from these patient-centric data capturing applications, through one web-based, intuitive interface.



myMedidata was built using insights generated by Medidata’s Patient Centricity by Design framework, where patient advocates regularly engage and provide direct input into the myMedidata software design and development life cycle. myMedidata allows patients to view their own clinical data (current and historical). Patients’ engagement with their study teams are enhanced via friendly reminders, progress tracking, and continued support throughout their studies. By providing a better overall study experience, patients are more likely to actively participate in and remain on their clinical trial.

myMedidata — Web-Based eConsent

To enroll in a new study virtually, patients are invited to create their myMedidata account, then are guided through an electronic consenting process, also known as eConsent. The consenting process is reviewed through a myMedidata LIVE visit with the patient and their study team - should the patient have any questions or concerns they'd like to discuss. Upon full understanding of the consent, the patient virtually signs their web-based eConsent.

myMedidata LIVE — Video Visits

During the COVID-19 pandemic, many clinical trials were paused in part due to the patient's inability to travel to the trial site and the trial monitors' inability to carry out their site initiation visits. myMedidata LIVE goes beyond the confines of a patient-study team virtual visit. Instead, myMedidata LIVE enables any two or more individuals to engage over a web-based video conference, not only giving sites and patients the ability to connect but also the sponsors' site monitors to meet with site study teams for continued reporting and study monitoring.


myMedidata — Web-Based eCOA

Throughout the trial life cycle, patients access their myMedidata accounts to virtually complete any necessary electronic clinical outcome assessment. Study teams configure forms needed and the patient logs into myMedidata to complete the web-based forms.

COVID-19 Symptom Tracker

A new feature of myMedidata includes the complimentary COVID-19 Symptom Tracker-enabling patients on any active clinical study (regardless of therapeutic focus) to monitor and track their COVID-19 symptoms in order to better track their progression, remain active in any current clinical trials while providing more accurate trial data. The COVID-19 Symptom Tracker is also available to non-Medidata users upon signing a customer agreement. Working with the sponsor, site study teams identify appropriate patients and offer them the opportunity to participate. Patients who decide to “opt in” receive a “Golden Ticket” or unique identifier that provides secure access to myMedidata. Patients virtually access myMedidata, enroll and virtually enter their symptoms throughout the study. The COVID-19 Symptom Tracker is available in US-English, French, Spanish (European and Latin American), Mandarin, Japanese and Korean.

COVID-19 Symptom Tracker How it Works



- 1 Participating sites distribute golden ticket codes for each patient. Codes are pre-mapped to the Rave subject IDs for each patient
- 2 Patient opts-in
- 3 Patient creates an account and tracks symptoms the first time
- 4 a If no symptoms are flagged, the patient is reminded to repeat weekly
- 4 b If symptoms are flagged, the patient is reminded to repeat daily
- 5 Data can be integrated with study information to provide value for scientific research and other use cases

myMedidata — Trial Virtualization

myMedidata offers Sponsors and CROs a streamlined and trusted approach to virtualizing clinical trials. Recognizing that all trials will not be 100% virtual, Medidata’s “Trial Dial” functionality allows sponsors to strike the right balance between traditional and virtual visits (hybrid trial) to deliver a true patient-centric study with more engaged and dynamic patient participation. Since myMedidata can be used for any Medidata study whether traditional or remote, the need for integrating disparate solutions and reconciliation of data is reduced. The number of vendors required to provide virtualization and/or patient engagement offerings is also minimized, streamlining the operations and reducing the costs of setting up and maintaining multiple systems. Risk is mitigated when virtualizing any aspect of a clinical trial, since the unified Medidata Rave Clinical Cloud™, used for patient data capture at the site, is the same platform used to capture patient data from myMedidata.


The following are the key benefits of myMedidata:

- Unified dashboard for patients to access to their clinical trial data (current or past)
- Web-based eConsent
- myMedidata LIVE video visits with study staff
- Web-based eCOAs throughout the study
- Notifications/ reminders sent to patients - improving protocol adherence
- COVID-19 Symptom Tracker available on all studies
- Enablement of virtual and hybrid clinical trials

The Future of myMedidata

New functionality will be added to myMedidata throughout 2020 and 2021 beginning with additional support for virtual trials. Future functionality on myMedidata will include:

- Patient engagement via community access to resources and other community members
- Patient view of their trial data
- Patient access to alternative clinical trials for participation
- Long term follow up
- Viewing and tracking of mobile nurses
- IMP shipments



About Medidata

Medidata is leading the digital transformation of life sciences, creating hope for millions of patients. Medidata helps generate the evidence and insights to help pharmaceutical, biotech, medical device and diagnostics companies, and academic researchers accelerate value, minimize risk, and optimize outcomes. More than one million registered users across 1,500 customers and partners access the world's most-used platform for clinical development, commercial, and real-world data.

Medidata, a Dassault Systèmes company (Euronext Paris: #13065, [DSY.PA](https://www.dsy.pa)), is headquartered in New York City and has offices around the world to meet the needs of its customers. Discover more at www.medidata.com and follow us @medidata, The Operating System for Life Sciences™.

Medidata, Medidata Rave and Acorn AI are registered trademarks of Medidata Solutions, Inc., a wholly owned subsidiary of Dassault Systèmes. info@medidata.com | +1 866 515 6044

Medidata Rave Clinical Cloud™

Cloud-based clinical research solutions | Innovative technology | Data-driven analytics
Reduced costs | Improved time to market | Faster decisions | Minimized risk